Research programme: RNA interference-based therapeutics - Intradigm/Sequitur

Drug Profile

Research programme: RNA interference-based therapeutics - Intradigm/Sequitur

Alternative Names: RNA interference-based therapeutics research programme - Intradigm; RNAi-based therapeutics research programme - Intradigm

Latest Information Update: 14 Jul 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intradigm Corporation; Sequitur
  • Developer Silence Therapeutics
  • Class RNA
  • Mechanism of Action RNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 09 Dec 2003 Sequitur has been acquired by Invitrogen Corporation
  • 24 Jun 2003 Intradigm and Sequitur have entered into an agreement to co-promote and co-develop RNAi-based therapeutics in the USA for diseases including cancer
  • 27 Aug 2002 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top